Previous retrospective studies comparing induction regimens for NPM1 mutated AML also showed that venetoclax with HMA was highly effective, achieving high rates of remissions with MRD negativity (75% versus 27% of patients receiving just HMA) and durable remissions [29,30]. Here, NPM1 is linked to acute myeloid leukemia.